Prudence Tettey1, Steve Simpson2, Bruce Taylor2, Leigh Blizzard2, Anne-Louise Ponsonby3, Terence Dwyer3, Karam Kostner4, Ingrid van der Mei2. 1. Menzies Research Institute Tasmania, University of Tasmania, Australia. Electronic address: prudence.tettey@utas.edu.au. 2. Menzies Research Institute Tasmania, University of Tasmania, Australia. 3. Murdoch Children's Research Institute, University of Melbourne, Australia. 4. Mater Hospital, University of Queensland, Australia.
Abstract
BACKGROUND: There is increasing evidence that serum lipids and apolipoproteins may be associated with multiple sclerosis (MS) clinical course. OBJECTIVE: To investigate the associations between serum lipids, apolipoproteins, body mass index and relapse in MS. METHODS: A prospective cohort of 141 participants with relapsing-remitting MS was followed from 2002 to 2005. Serum lipid and apolipoprotein levels were measured biannually, and body mass index at baseline. The association with hazard of relapse was assessed using survival analysis. RESULTS: Neither body mass index nor any of the lipid-related measures were associated with the hazard of relapse. CONCLUSION: Serum lipid profile and body mass index are not associated with the hazard of relapse in MS.
BACKGROUND: There is increasing evidence that serum lipids and apolipoproteins may be associated with multiple sclerosis (MS) clinical course. OBJECTIVE: To investigate the associations between serum lipids, apolipoproteins, body mass index and relapse in MS. METHODS: A prospective cohort of 141 participants with relapsing-remitting MS was followed from 2002 to 2005. Serum lipid and apolipoprotein levels were measured biannually, and body mass index at baseline. The association with hazard of relapse was assessed using survival analysis. RESULTS: Neither body mass index nor any of the lipid-related measures were associated with the hazard of relapse. CONCLUSION: Serum lipid profile and body mass index are not associated with the hazard of relapse in MS.
Authors: Kaarina Kowalec; Kyla A McKay; Scott B Patten; John D Fisk; Charity Evans; Helen Tremlett; Ruth Ann Marrie Journal: Neurology Date: 2017-11-08 Impact factor: 9.910
Authors: Ruth Ann Marrie; Aaron Miller; Maria Pia Sormani; Alan Thompson; Emmanuelle Waubant; Maria Trojano; Paul O'Connor; Kirsten Fiest; Nadia Reider; Stephen Reingold; Jeffrey A Cohen Journal: Neurology Date: 2016-02-10 Impact factor: 9.910
Authors: Claudia Helena Marck; Sandra Leanne Neate; Keryn Louise Taylor; Tracey Joy Weiland; George Alexander Jelinek Journal: PLoS One Date: 2016-02-05 Impact factor: 3.240